Apellis Pharmaceuticals Stock Buy Hold or Sell Recommendation
| APLS Stock | USD 48.72 1.08 2.27% |
Given the investment horizon of 90 days and your conservative risk appetite, our recommendation regarding Apellis Pharmaceuticals is 'Strong Sell'. Macroaxis provides Apellis Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding APLS positions. The advice algorithm takes into account all of Apellis Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Apellis Pharmaceuticals' buy or sell advice are summarized below:
Real Value 59.99 | Target Price 71.71 | Hype Value 48.99 | Market Value 48.72 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Apellis Pharmaceuticals given historical horizon and risk tolerance towards Apellis Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Apellis Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Apellis |
Execute Apellis Pharmaceuticals Buy or Sell Advice
The Apellis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Apellis Pharmaceuticals. Macroaxis does not own or have any residual interests in Apellis Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Apellis Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Apellis Pharmaceuticals Trading Alerts and Improvement Suggestions
| Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 69.79 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (594.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Apellis Pharmaceuticals, Inc. to Post Q1 2024 Earnings of Per Share, Wedbush Forecasts - Defense World |
Apellis Pharmaceuticals Returns Distribution Density
The distribution of Apellis Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Apellis Pharmaceuticals' future price movements. The chart of the probability distribution of Apellis Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Apellis Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Apellis Pharmaceuticals returns is essential to provide solid investment advice for Apellis Pharmaceuticals.
| Mean Return | -0.4 | Value At Risk | -6.72 | Potential Upside | 3.12 | Standard Deviation | 2.92 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Apellis Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Apellis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Apellis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apellis Pharmaceuticals backward and forwards among themselves. Apellis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Apellis Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2023-12-31 | 2.5 M | Assenagon Asset Management Sa | 2023-12-31 | 2.1 M | Fmr Inc | 2023-12-31 | 2.1 M | Boxer Capital Llc | 2023-12-31 | 1.7 M | Geode Capital Management, Llc | 2023-12-31 | 1.6 M | Artal Group S A | 2023-12-31 | 1.4 M | Pictet Asset Manangement Sa | 2023-12-31 | 1.3 M | Polar Capital Holdings Plc | 2023-12-31 | 1.1 M | Logos Global Management Lp | 2023-12-31 | 950 K | Wellington Management Company Llp | 2023-12-31 | 16.4 M | Ecor1 Capital, Llc | 2023-12-31 | 11.2 M |
Apellis Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 175.7M | 215.1M | 74.7M | (88.7M) | (200.8M) | (190.7M) | |
| Free Cash Flow | (212.8M) | (165.9M) | (564.2M) | (515.3M) | (595.5M) | (565.7M) | |
| Other Non Cash Items | 2.7M | 15.8M | 6.3M | 61.6M | 395.0M | 414.7M | |
| Net Income | (304.7M) | (344.9M) | (746.4M) | (652.2M) | (528.6M) | (502.2M) | |
| End Period Cash Flow | 352.0M | 567.0M | 641.8M | 553.1M | 352.3M | 289.7M | |
| Change To Netincome | 37.8M | 148.6M | 274.3M | 152.1M | 174.9M | 183.7M |
Apellis Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Apellis Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Apellis Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Apellis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.47 | |
β | Beta against NYSE Composite | 0.75 | |
σ | Overall volatility | 3.00 | |
Ir | Information ratio | -0.17 |
Apellis Pharmaceuticals Volatility Alert
Apellis Pharmaceuticals exhibits very low volatility with skewness of 0.0 and kurtosis of 1.63. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Apellis Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Apellis Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Apellis Pharmaceuticals Fundamentals Vs Peers
Comparing Apellis Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Apellis Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Apellis Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Apellis Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Apellis Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Apellis Pharmaceuticals to competition |
Note: Disposition of 1500 shares by Dunlop A. Sinclair of Apellis Pharmaceuticals at 13.19 subject to Rule 16b-3 [view details]
Apellis Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Apellis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 48108.56 | |||
| Daily Balance Of Power | 0.532 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 48.99 | |||
| Day Typical Price | 48.9 | |||
| Price Action Indicator | 0.27 | |||
| Period Momentum Indicator | 1.08 |
About Apellis Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Apellis Pharmaceuticals? Buying financial instruments such as Apellis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 7.6M | 124.6M | 203.6M | 213.8M | Total Assets | 881.8M | 760.2M | 788.7M | 425.1M |
Use Investing Ideas to Build Portfolios
In addition to having Apellis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Giant Impact Thematic Idea Now
Giant Impact
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Apellis Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Apellis Stock analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.45) | Revenue Per Share 3.342 | Quarterly Revenue Growth 5.459 | Return On Assets (0.42) | Return On Equity (2.90) |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.